Overview

Upcoming Event

ACR Convergence 2020

Stock Information

Symbol

Nasdaq: CRBP

Price

Loading...

Change

Loading...

MKT Cap

Loading...

Volume

Loading...

Company Overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist that resolves chronic inflammation and limits fibrosis in animal and human models. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Third-party websites are provided for convenience only. Corbus Pharmaceuticals Holdings, Inc. does not approve of, or endorse any of the content. Corbus Pharmaceuticals Holdings, Inc. does not maintain, control or monitor the content of third-party websites in any way.